TrialSignal transduction and targeted therapy2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
Lin Gui et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.